Analyzing ProSomnus (OSA) and Its Competitors

ProSomnus (NASDAQ:OSA) is one of 229 public companies in the “Surgical & medical instruments” industry, but how does it compare to its rivals? We will compare ProSomnus to similar companies based on the strength of its valuation, profitability, dividends, analyst recommendations, risk, institutional ownership and earnings.

Profitability

This table compares ProSomnus and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProSomnus	-87.14%	N/A	-106.30%
ProSomnus Competitors	-752.97%	-144.42%	-28.58%

Risk & Volatility

ProSomnus has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, ProSomnus’ rivals have a beta of 1.10, meaning that their average stock price is 10% more volatile than the S&P 500.

Insider and Institutional Ownership

70.0% of ProSomnus shares are owned by institutional investors. Comparatively, 48.7% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 7.7% of ProSomnus shares are owned by company insiders. Comparatively, 15.3% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares ProSomnus and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ProSomnus	$27.65 million	-$24.09 million	-0.09
ProSomnus Competitors	$1.05 billion	$4.24 million	-7.94

ProSomnus’ rivals have higher revenue and earnings than ProSomnus. ProSomnus is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations for ProSomnus and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProSomnus	0	1	2	0	2.67
ProSomnus Competitors	1592	4305	8444	223	2.50

ProSomnus currently has a consensus price target of $2.33, suggesting a potential upside of 1,566.67%. As a group, “Surgical & medical instruments” companies have a potential upside of 29.46%. Given ProSomnus’ stronger consensus rating and higher probable upside, equities analysts plainly believe ProSomnus is more favorable than its rivals.

Summary

ProSomnus beats its rivals on 7 of the 13 factors compared.

ProSomnus Company Profile

ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California.